Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Clinical trial NCT05636111 · RECRUITING
Trial details
- NCT number
- NCT05636111
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-12
- Primary completion
- 2026-12-31
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.